Literature DB >> 6703817

Clinical and chemical assessment of thyroid function during therapy with amiodarone.

J A Amico, V Richardson, B Alpert, I Klein.   

Abstract

Clinical and chemical variables of thyroid function were studied in 26 patients with symptomatic ventricular tachyarrhythmias before and during long-term oral treatment with amiodarone. The mean (+/-SEM) pretreatment thyroxine (T4) level in the 26 patients was 7.32 +/- 0.33 micrograms/dL, and increased notably to 10.15 +/- 0.47 micrograms/dL by 30 to 120 days after treatment. The free thyroxine index (FT4I) was also notably elevated. Clinical hyperthyroidism or goiter did not develop, but clinical hypothyroidism occurred in four patients during and in one patient after discontinuation of amiodarone treatment. Notable titers of antithyroid antibodies were found in the serum of two of the five and a family history of thyroid disease was present in three of the five hypothyroid patients. An elevation of both the T4 level and the FT4I above the normal range is an expected finding in patients receiving amiodarone and does not by itself indicate hyperthyroidism. Patients with positive antithyroid antibodies or a family history of thyroid disease prior to treatment with amiodarone may be at an increased risk of hypothyroidism developing when treated with this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703817

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

2.  Management of amiodarone-related thyroid problems.

Authors:  Shashithej K Narayana; David R Woods; Christopher J Boos
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

Review 3.  Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.

Authors:  L Bartalena; F Bogazzi; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

Review 4.  Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy.

Authors:  C M Newman; A Price; D W Davies; T A Gray; A P Weetman
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 5.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

6.  Long-term amiodarone therapy raises serum cholesterol.

Authors:  A A Lakhdar; E Farish; W S Hillis; F G Dunn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Uptake of amiodarone by thyroidal and non-thyroidal cell lines.

Authors:  F Bogazzi; F Raggi; F Ultimieri; D Russo; C Cosci; P Cecchetti; E Dell'Unto; C Sardella; M Tonacchera; P Vitti; L Benzi; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

8.  Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands.

Authors:  C Broussolle; X Ducottet; C Martin; Y Barbier; H Bornet; G Noel; J Orgiazzi
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

Review 9.  The Role of Thyroid Diseases and their Medications in Cardiovascular Disorders: A Review of the Literature.

Authors:  Negar Omidi; Mohammadrafie Khorgami; Farbod Z Tajrishi; Amirhosein Seyedhoseinpour; Parichehr Pasbakhsh
Journal:  Curr Cardiol Rev       Date:  2020

10.  Assessment of the Adequacy of Thyroid Hormone Replacement Therapy in Hypothyroidism.

Authors:  Matvey Brokhin; Sara Danzi; Irwin Klein
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-20       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.